Daniela Mercatelli

Ferrara, 44121, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Enhancement of D1 dopaminergic responses in aged LRRK2 G2019S knock-in mice.

Enhancement of D1 dopaminergic responses in aged LRRK2 G2019S knock-in mice.

Journal: Neurobiology of disease

Published: January 22, 2025

Viral mediated α-synuclein overexpression results in greater transgene levels and α-synuclein overload in mice bearing kinase dead mutation of LRRK2.

Viral mediated α-synuclein overexpression results in greater transgene levels and α-synuclein overload in mice bearing kinase dead mutation of LRRK2.

Journal: Scientific reports

Published: September 26, 2024

Dopamine Transporter, PhosphoSerine129 α-Synuclein and α-Synuclein Levels in Aged LRRK2 G2019S Knock-In and Knock-Out Mice.

Dopamine Transporter, PhosphoSerine129 α-Synuclein and α-Synuclein Levels in Aged LRRK2 G2019S Knock-In and Knock-Out Mice.

Journal: Biomedicines

Published: March 25, 2022

In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity.

In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity.

Journal: Neurobiology of disease

Published: September 21, 2021

Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo.

Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo.

Journal: Neurobiology of disease

Published: July 16, 2021

Early Dysfunction of Substantia Nigra Dopamine Neurons in the ParkinQ311X Mouse.

Early Dysfunction of Substantia Nigra Dopamine Neurons in the ParkinQ311X Mouse.

Journal: Biomedicines

Published: April 01, 2021

Regulator of G-Protein Signalling 4 (RGS4) negatively modulates nociceptin/orphanin FQ opioid receptor signalling: Implication for l-Dopa-induced dyskinesia.

Regulator of G-Protein Signalling 4 (RGS4) negatively modulates nociceptin/orphanin FQ opioid receptor signalling: Implication for l-Dopa-induced dyskinesia.

Journal: British journal of pharmacology

Published: February 24, 2021

Pharmacological antagonism of kainate receptor rescues dysfunction and loss of dopamine neurons in a mouse model of human parkin-induced toxicity.

Pharmacological antagonism of kainate receptor rescues dysfunction and loss of dopamine neurons in a mouse model of human parkin-induced toxicity.

Journal: Cell death & disease

Published: July 07, 2020

Discovery and Structure-Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson's Disease Models.

Discovery and Structure-Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson's Disease Models.

Journal: Journal of medicinal chemistry

Published: January 18, 2020

Managing Parkinson's disease: moving ON with NOP.

Managing Parkinson's disease: moving ON with NOP.

Journal: British journal of pharmacology

Published: July 01, 2019

Gene Co-expression Analysis Identifies Histone Deacetylase 5 and 9 Expression in Midbrain Dopamine Neurons and as Regulators of Neurite Growth via Bone Morphogenetic Protein Signaling.

Gene Co-expression Analysis Identifies Histone Deacetylase 5 and 9 Expression in Midbrain Dopamine Neurons and as Regulators of Neurite Growth via Bone Morphogenetic Protein Signaling.

Journal: Frontiers in cell and developmental biology

Published: June 14, 2019

Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes.

Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes.

Journal: Pharmacology research & perspectives

Published: April 17, 2019

Showing 1-12 of 22

Last Updated: 09/26/2026